Medications for ADHD

  • J. Gordon Millichap
Chapter

Abstract

Medications, especially central nervous system stimulants, are an important part of treatment of ADHD. The use of stimulants for the treatment of hyperactive behavior in children was first described in 1937, beginning with amphetamines. Controlled trials of methylphenidate (Ritalin®) in the 1960s demonstrated significant benefits without serious side effects. In addition to a lessening of motor activity, focus and attention were increased and schoolwork, grades, and social behavior were improved. In small to moderate doses, methylphenidate benefits learning without impairing creative or flexible thinking. The value of stimulant medication in the management of ADHD has withstood the test of time.

Keywords

Carbamazepine Dystonia Valproate Imipramine Sertraline 

References

  1. Abramowitz AJ, Dulcan MK, et al. ADHD children’s responses to stimulant medication and two intensities of a behavioral intervention. Beha Modif. 1992;16:193–203.CrossRefGoogle Scholar
  2. Ahmann PA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics. 1993;91:1101–1106.PubMedGoogle Scholar
  3. Auci DL, et al. Methylphenidate and the immune system (Letter to the editor). J Am Acad Child Adolesc Psychiatry. 1997;36:1015–1016.PubMedCrossRefGoogle Scholar
  4. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546–557.Google Scholar
  5. Barkley RA, et al. Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate. Pediatrics. 1991;87:519–531.PubMedGoogle Scholar
  6. Barkley RA, et al. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98:1089–1095.PubMedGoogle Scholar
  7. Barrickman LL, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649–657.PubMedCrossRefGoogle Scholar
  8. Biederman J, et al. Diagnostic continuity between child and adolescent ADHD. J Am Acad Child Adolesc Psychiatry. 1998;37:305–313.PubMedCrossRefGoogle Scholar
  9. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorders: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116:e777–784.Google Scholar
  10. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450–463.PubMedCrossRefGoogle Scholar
  11. Bowen J, et al. Stimulant medication and attention-deficit hyperactivity disorder. The child’s perspective. AJDC. 1991;145:291–295.PubMedGoogle Scholar
  12. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry. 1937;94:577–585.Google Scholar
  13. Bradley C. Benzedrine and dexedrine in the treatment of children’s behavior disorders. Pediatrics. 1950;5:24–36.PubMedGoogle Scholar
  14. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115:e749–757.PubMedCrossRefGoogle Scholar
  15. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1025–1032.PubMedCrossRefGoogle Scholar
  16. Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry. 1997;36:539–544.Google Scholar
  17. Casat CD, et al. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1987;23:120–122.PubMedGoogle Scholar
  18. Castellanos FX, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36:58.CrossRefGoogle Scholar
  19. Clay TH, et al. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull. 1988;24:143–148.PubMedGoogle Scholar
  20. Conners CK, Eisenberg L. The effects of methylphenidate on symptomatology and learning in disturbed children. Am J Psychiatry. 1963;120:458–464.PubMedGoogle Scholar
  21. Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118:e704–e710.PubMedCrossRefGoogle Scholar
  22. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189–198.Google Scholar
  23. Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration. J Am Med Assoc. 1976;235:1349–1351.CrossRefGoogle Scholar
  24. Douglas VI, et al. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1995;34:877–885.PubMedCrossRefGoogle Scholar
  25. DuPaul GJ, Rapport MD. Does methylphenidate normalize the classroom performance of children with attention deficit disorder? J Am Acad Child Adolesc Psychiatry. 1993;32:190–198.PubMedCrossRefGoogle Scholar
  26. Dulcan MK. Treatment of children and adolescents. In: RE Hales, SC Yodofsky, JA Talbott (eds). The American Psychiatric Press Textbook of Psychiatry. 2nd ed. Washington, DC: American Psychiatric Press; 1994:pp 1209–1250Google Scholar
  27. Dworkin N. Atomoxetine induced electrocardiographic repolarization changes with palpitations in a child. J Am Acad Child Adolesc Psychiatry. 2005;44:510.PubMedCrossRefGoogle Scholar
  28. Feeney DJ, Klykylo WM. Medication-induced seizures (Letter to the editor). J Am Acad Child Adolesc Psychiatry. 1997;36:1018–1019.PubMedCrossRefGoogle Scholar
  29. Feldman H, et al. Methylphenidate in children with seizures and attention-deficit disorder. AJDC. 1989;143:1081–1086.PubMedGoogle Scholar
  30. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13:614–620.PubMedGoogle Scholar
  31. Funk JB, et al. Attention deficit hyperactivity disorder, creativity, and the effects of methylphenidate. Pediatrics. 1993;91:816–819.PubMedGoogle Scholar
  32. Gilbert DL, Wang Z, Sallee FR, et al. Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain. 2006;129:2038–2046.PubMedCrossRefGoogle Scholar
  33. Gillberg C, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. Arch Gen Psychiatry. 1997;54:857–864.PubMedCrossRefGoogle Scholar
  34. Goldman LS, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Am Med Assoc. 1998;279:1100–1107.CrossRefGoogle Scholar
  35. Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:817–823.PubMedCrossRefGoogle Scholar
  36. Gross-Tsur V, et al. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective? J Pediatr. 1997;130:670–674.PubMedCrossRefGoogle Scholar
  37. Hammer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol. 2001;24:99–102.CrossRefGoogle Scholar
  38. Handen BL, et al. Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry. 1994;33:1185–1193.PubMedCrossRefGoogle Scholar
  39. Hochman JA, et al. Exacerbation of autoimmune hepatitis: another hepatotoxic effect of pemoline therapy. Pediatrics. 1998;101:106–108.PubMedCrossRefGoogle Scholar
  40. Hood J, Baird G, Rankin PM, Isaacs E. Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2005;47:408–414.PubMedCrossRefGoogle Scholar
  41. Jensen PS, et al. Collaborative multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1997;54:865–870.PubMedCrossRefGoogle Scholar
  42. Johnston C, Pelham WE, Hoza J, Sturges J. Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry. 1988;27:806–810.PubMedCrossRefGoogle Scholar
  43. Keuthen NJ, et al. Retrospective review of treatment outcome for 63 patients with trichotillomania. Am J Psychiatry. 1998;155:560–561.PubMedGoogle Scholar
  44. Kouris S. Methylphenidate-induced obsessive-compulsiveness. J Am Acad Child Adolesc Psychiatry. 1998;37:135.PubMedCrossRefGoogle Scholar
  45. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:919–927.PubMedCrossRefGoogle Scholar
  46. Lopez FA, Ginsberg LD, Arnold V. Effect of lisdexamfetmine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. Postgrad Med. 2008;120:89–102.PubMedCrossRefGoogle Scholar
  47. Malhotra S, Santosh PJ. An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:364–371.PubMedCrossRefGoogle Scholar
  48. Mannuzza S, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998;155:493–498.PubMedGoogle Scholar
  49. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159:572–578.PubMedCrossRefGoogle Scholar
  50. Martin A, Scahill L, Vitulano L, King RA. Stimulant use and trichotillomania. J Am Acad Child Adolesc Psychiatry. 1998;37:349–350.Google Scholar
  51. McBride MC, et al. Use of Ritalin in the hyperactive patient with seizures controlled by anticonvulsant drugs. Ann Neurol. 1986;20:428.Google Scholar
  52. McGough JJ, Biederrman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Aderrall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:530–538.PubMedCrossRefGoogle Scholar
  53. Millichap JG, et al. Hyperkinetic behavior and learning disorders: III. Battery of neuropsychological tests in controlled trial of methylphenidate. Am J Dis Child. 1968;116:235–244.PubMedGoogle Scholar
  54. Millichap JG. Drugs in management of minimal brain dysfunction. Ann N Y Acad Sci. 1973;205:321–334.PubMedCrossRefGoogle Scholar
  55. Millichap JG (Ed). Learning Disabilities and Related Disorders: Facts and Current Issues. Chicago, IL: Year Book Medical Publishers; 1977.Google Scholar
  56. Millichap JG. Usage of CNS stimulants for ADHD by pediatric neurologists. Ped Neur Briefs. 1996;10:65.Google Scholar
  57. Millichap JG. Progress in Pediatric Neurology III. Chicago, IL: PNB Publishers; 1997a.Google Scholar
  58. Millichap JG. Medication-induced seizures in ADHD. Ped Neur Briefs. 1997b;11:63, May.Google Scholar
  59. Millichap MG. Locus of control in children with ADHD. Personal communication. 1998.Google Scholar
  60. Millichap JG, Swisher CN. Ritalin-induced seizures in two children with ADHD. Ped Neur Briefs. 1997;11:38, May.Google Scholar
  61. Miyazaki M, Ito H, Saijo T, et al. Favorable response of ADHD with giant SEP to extended-release valproate. Brain Dev. 2006;28:470–472.PubMedCrossRefGoogle Scholar
  62. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123:611–616.PubMedCrossRefGoogle Scholar
  63. Musten LM, et al. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry. 1997;36:1407–1415.PubMedCrossRefGoogle Scholar
  64. National Institute of Mental Health. Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113:754–761.CrossRefGoogle Scholar
  65. Nolan EE, Gadow KD. Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36:597–604.PubMedCrossRefGoogle Scholar
  66. O‘Toole K, Abramowitz A, Morris R, Dulcan M. Effects of methylphenidate on attention and nonverbal learning in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:531–538.PubMedCrossRefGoogle Scholar
  67. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90:801–806.PubMedCrossRefGoogle Scholar
  68. Rajesh AS, Bates G, Wright JGC. Atomoxetine-induced electrocardiogram changes. Arch Dis Child. 2006;91:1023–1024.PubMedCrossRefGoogle Scholar
  69. Rapport MD, et al. Attention deficit disorder and methylphenidate: Normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry. 1994;33:882–893.PubMedCrossRefGoogle Scholar
  70. Rapport MD, Denney C. Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: Is body mass predictive of clinical response? J Am Acad Child Adolesc Psychiatry. 1997;36:523–530.PubMedCrossRefGoogle Scholar
  71. Riggs PD. Approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:331–332.PubMedCrossRefGoogle Scholar
  72. Rosh JR, et al. Four cases of severe hepatotoxicity associated with pemoline: Possible autoimmune pathogenesis. Pediatrics. 1998;101:921–923.PubMedCrossRefGoogle Scholar
  73. Safer D, et al. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med. 1972;287:217.PubMedCrossRefGoogle Scholar
  74. Safer DJ, et al. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084–1088.PubMedGoogle Scholar
  75. Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979;36:212–217.Google Scholar
  76. Schachar RJ, et al. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36:754–763.PubMedCrossRefGoogle Scholar
  77. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol. 1997;16:14–16.PubMedCrossRefGoogle Scholar
  78. Silva RR, et al. Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 1996;35:352–358.PubMedCrossRefGoogle Scholar
  79. Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A. Treatment of children with attention-deficit/hyperactivity disorder: Results of a randomized, multicenter, double-blind, crossover study of extended-release D-methylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull. 2008;41:19–33.PubMedGoogle Scholar
  80. Simeon JG, et al. Bupropion effects in attention deficit and conduct disorders. Can J Psych. 1986;31:581–585.Google Scholar
  81. Smith BH, et al. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry. 1998;378:314–321.CrossRefGoogle Scholar
  82. Spencer T, et al. Bupropion exacerbates tics in children with attention deficit hyperactivity disorder and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32:211–214.PubMedCrossRefGoogle Scholar
  83. Spencer T, et al. Pharmacotherapy of ADHD reviewed. J Am Acad Child Adolesc Psychiatry. 1996;35:409–432.PubMedCrossRefGoogle Scholar
  84. Spencer TJ, Faraone SV, Biederman J, et al. Does prolonged therapy with long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45:527–537.PubMedCrossRefGoogle Scholar
  85. Sprague R, Sleator E. Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science. 1977;198:1274–1276.PubMedCrossRefGoogle Scholar
  86. Stein MA, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics. 1996;98:748–756.PubMedGoogle Scholar
  87. Swanson JM, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 1998;37:519–526, May.PubMedCrossRefGoogle Scholar
  88. Swartwood MO, et al. Methylphenidate effects on EEG, behavior, and performance in boys with ADHD. Pediatr Neurol. 1998;18:244–250.PubMedCrossRefGoogle Scholar
  89. Tannock R, Schachar RJ, Carr RP, Logan GD. Dose response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics. 1989;84:648–657.Google Scholar
  90. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. J Am Med Assoc. 2009;301:1148–1154.CrossRefGoogle Scholar
  91. Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: Results from a national sample. Pediatrics. 2008;12:e1–e5.CrossRefGoogle Scholar
  92. Whalen CK, et al. Does stimulant medication improve the peer status of hyperactive children? J Consult Clin Psychol. 1989;57:5435–5449.Google Scholar
  93. Whalen CK, Henker B, et al. Natural social behaviors in hyperactive children: Dose effects of methylphenidate. J Consult Clin Psychol. 1987;55:187–193.PubMedCrossRefGoogle Scholar
  94. Wilens TE, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:1491–1501.PubMedCrossRefGoogle Scholar
  95. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160:82–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • J. Gordon Millichap
    • 1
  1. 1.Division of NeurologyNorthwestern University Medical School, Children’s Memorial HospitalChicagoUSA

Personalised recommendations